InvestorsHub Logo
Followers 4
Posts 236
Boards Moderated 0
Alias Born 05/27/2016

Re: xio8up post# 214

Saturday, 06/16/2018 9:12:24 AM

Saturday, June 16, 2018 9:12:24 AM

Post# of 789
Phase Ib/II study of duvelisib in combination with FCR (dFCR) achieves ORR of 94% and 76% bone marrow MRD negativity in frontline therapy in younger CLL patients

Duvelisib demonstrates robust clinical activity in CLL with 73% ORR and a median of 15 month PFS in the DUO crossover study of patients who became relapsed/refractory to ofatumumab in DUO™

Additional data support the hypothesis that duvelisib, a first-in-class dual inhibitor of PI3K delta/gamma, targets malignant B-cells directly and modulates the tumor microenvironment


Huge News!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VSTM News